Annual report pursuant to Section 13 and 15(d)

Liquidity (Details Narrative)

v3.19.1
Liquidity (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Accumulated deficit $ (121,370,240) $ (65,698,101)
Cash and cash equivalents 41,748,468 62,537,495
Proceeds from sale of stock 12,052,645 $ 78,891,699
Kaken Pharmaceutical Co., Ltd. [Member]    
Upfront payment, recieved from related party 27,000,000  
Cystic Fibrosis Foundation [Member] | Investment Agreement [Member]    
Proceeds from Royalty $ 2,700,000  
Upfront payment, percentage 10.00%  
Cystic Fibrosis Foundation [Member] | Investment Agreement [Member] | January 2019 Offering [Member]    
Proceeds from sale of stock $ 37,600,000